Your Article Summary
See Latest ArticlesNew directions in the treatment of systemic lupus erythematosus
Current Medical Research and Opinion, 07/01/09
Kalunian K et al. – Biologic compounds that target specific immunologic mechanisms offer a new paradigm in the treatment of systemic lupus erythematosus (SLE); may reverse the course of the disease and might provide some new alternatives to reduce symptoms and limit tissue damage without undue contribution to overall morbidity and mortality.
Methods- Review to provide an up-to-date overview of:
- Treatment approaches for SLE, highlighting the multiplicity and heterogeneity of clinical symptoms that underlie therapeutic decisions
- Currently available therapies, their mechanisms and associated side-effects
- Recent developments with biologic treatments including rituximab, epratuzumab, TNF inhibitors, and belimumab
- MEDLINE literature search for ‘SLE’ and ‘damage’ and ‘treatment’ was undertaken for 1996–2008
- Secondary citations obtained from selected manuscripts
- Individual case studies were excluded
- SLE is an autoimmune disease involving multiple organ systems, a clinical pattern of flares and remissions, and the presence of ANA
- Early symptoms involve skin and joints
- Disease morbidity and mortality are associated with CV events and damage to major organs, particularly the kidneys
- Many of the current therapeutic options are considered to be inadequate because of toxicities, organ damage, and insufficient control of disease
- New treatments are mainly focused on the targeted immunosuppressive actions provided by biologic therapy
- Although their long-term beneficial or harmful effects are unclear, their precise molecular targeting may advance the cause of individualized molecular medicine
Related Articles
Ten cases of systemic lupus erythematosus related to hepatitis B vaccine
Lupus, 11/09/09
Relevance Score: 84%
Safety of vaccination of patients with systemic lupus erythematosus
Lupus, 11/04/09
Relevance Score: 84%
Infection—genetics relationship in systemic lupus erythematosus
Lupus, 11/05/09
Relevance Score: 83%
Molecular mimicry in systemic lupus erythematosus
Lupus, 11/13/09
Relevance Score: 82%
Vaccination, atherosclerosis and systemic lupus erythematosus
Lupus, 11/05/09
Relevance Score: 82%
Today in Systemic Lupus (SLE)...keeping you current
Receive free subspecialty "5-minute updates" via email
Interferon-[alpha] mediates suppression of C-reactive protein: Explanation for muted C-reactive protein response in lupus flares?
Arthritis & Rheumatism, 12/06/09
Serum blc/cxcl13 concentrations and renal expression of cxcl13/cxcr5 in patients with systemic lupus erythematosus and lupus nephritis
Journal of Rheumatology, 12/06/09
Progressive multifocal leukoencephalopathy: A national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases
Arthritis & Rheumatism, 12/04/09